ORIC Pharmaceuticals Reports 35% ORR in HER2 Mutation Patients from Enozertinib Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy ORIC?
Source: Newsfilter
- Promising Trial Results: ORIC Pharmaceuticals' enozertinib (ORIC-114) demonstrated a 35% objective response rate (ORR) in previously treated NSCLC patients with HER2 exon 20 mutations during the Phase 1b trial, indicating its potential in treating resistant cancers.
- Good Safety Profile: The drug exhibited a manageable safety profile with mostly Grade 1 or 2 treatment-related adverse events, and only two patients discontinued treatment due to adverse events, highlighting its acceptability in clinical use.
- Enrollment Completed: As of the August 29, 2025 cutoff, 49 patients were enrolled, with 47% having baseline brain metastases, suggesting the drug's applicability in complex cases.
- Future Development Plans: ORIC plans to use the 80 mg dose for potential Phase 3 development, continuing enrollment and follow-up in EGFR mutation patients, with further updates expected in mid-2026, demonstrating the company's commitment to future clinical advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.240
Low
15.00
Averages
19.60
High
25.00
Current: 10.240
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: ORIC Pharmaceuticals CEO Jacob M. Chacko will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the latest advancements in their oncology drug development, which is expected to attract investor interest.
- Live Webcast: The presentation will be available via live webcast on the investor section of the company’s website, with a replay accessible for 90 days post-event, ensuring that investors unable to attend live can still access critical information.
- Product Candidates: ORIC's clinical-stage candidates include ORIC-944, an allosteric inhibitor for prostate cancer, and enozertinib (ORIC-114), targeting various genetically defined cancers, highlighting the company's potential in innovative drug development aimed at overcoming therapeutic resistance.
- Company Background: ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving patient lives by overcoming resistance in cancer, with offices in South San Francisco and San Diego, indicating a strategic presence in California's biotech hub.
See More
ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation
Price Target Increase: Wells Fargo raised the price target for ORIC Pharmaceuticals from $19 to $25, maintaining an Overweight rating, indicating confidence in the company's potential for growth.
Financial Position: As of September 30, ORIC Pharmaceuticals reported approximately $413 million in cash and investments, which is expected to support its operations through 2028 and fund upcoming Phase 3 trials.
Clinical Development: The company is making significant progress towards initiating Phase 3 trials for its lead candidates, ORIC-944 and enozertinib, which are anticipated to yield important data in the near future.
Investment Considerations: While ORIC is seen as a promising investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk, highlighting a competitive investment landscape.
See More
ORIC Pharmaceuticals Reports Enozerinib Clinical Data with 67% Response Rate in 1L Patients
- Clinical Trial Results: ORIC Pharmaceuticals presented data from the Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress, revealing a 67% objective response rate (ORR) in first-line patients, indicating the drug's potential in treating NSCLC with EGFR exon 20 mutations.
- Safety Analysis: Enozerinib demonstrated favorable tolerability with mostly Grade 1 or 2 adverse events, and only three patients discontinued treatment due to adverse reactions, suggesting a safety profile that outperforms competitor therapies.
- Performance in Brain Metastases: Among patients receiving the 80 mg dose, enozertinib achieved a 100% intracranial ORR and a 93% disease control rate (DCR), showcasing its exceptional efficacy in patients with brain metastases and reinforcing its competitive edge in the market.
- Future Development Plans: ORIC plans to update data in mid-2026 and may initiate a Phase 3 trial, reflecting the company's confidence in enozertinib and its strategic positioning in the oncology sector.
See More
ORIC Pharmaceuticals Reports 67% ORR in 1L Patients for Enozerinib at ESMO Asia 2025
- Clinical Trial Results: At the ESMO Asia Congress 2025, ORIC Pharmaceuticals announced that the Phase 1b trial of enozertinib achieved a 67% objective response rate (ORR) in first-line patients with EGFR exon 20 mutations, indicating strong efficacy that may surpass competitor benchmarks in treating NSCLC.
- Safety Analysis: Enozerinib demonstrated good tolerability with mostly Grade 1 or 2 treatment-related adverse events (TRAEs) and no significant off-target toxicities, as only three patients discontinued treatment due to TRAEs, highlighting its safety profile in clinical applications.
- Performance in Brain Metastasis Patients: Among patients receiving the 80 mg dose, enozertinib achieved a 100% intracranial ORR and a 93% disease control rate (DCR), underscoring its effectiveness in patients with brain metastases and reinforcing its potential in treating complex cases.
- Future Development Plans: ORIC plans to update data in mid-2026 and advance enozertinib into Phase 3 trials, indicating the company's confidence in the drug and its potential competitiveness in the market.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: ORIC Pharmaceuticals CEO Jacob M. Chacko will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the latest advancements in their oncology drug development, which is expected to attract investor interest.
- Live Webcast: The presentation will be available via live webcast on the investor section of the company’s website, with a replay accessible for 90 days post-event, ensuring that investors unable to attend live can still access critical information.
- Product Candidates: ORIC's clinical-stage candidates include ORIC-944, an allosteric inhibitor for prostate cancer, and enozertinib (ORIC-114), targeting various genetically defined cancers, highlighting the company's potential in innovative drug development aimed at overcoming therapeutic resistance.
- Company Background: ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving patient lives by overcoming resistance in cancer, with offices in South San Francisco and San Diego, indicating a strategic presence in California's biotech hub.
See More
ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation
Price Target Increase: Wells Fargo raised the price target for ORIC Pharmaceuticals from $19 to $25, maintaining an Overweight rating, indicating confidence in the company's potential for growth.
Financial Position: As of September 30, ORIC Pharmaceuticals reported approximately $413 million in cash and investments, which is expected to support its operations through 2028 and fund upcoming Phase 3 trials.
Clinical Development: The company is making significant progress towards initiating Phase 3 trials for its lead candidates, ORIC-944 and enozertinib, which are anticipated to yield important data in the near future.
Investment Considerations: While ORIC is seen as a promising investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk, highlighting a competitive investment landscape.
See More
ORIC Pharmaceuticals Reports Enozerinib Clinical Data with 67% Response Rate in 1L Patients
- Clinical Trial Results: ORIC Pharmaceuticals presented data from the Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress, revealing a 67% objective response rate (ORR) in first-line patients, indicating the drug's potential in treating NSCLC with EGFR exon 20 mutations.
- Safety Analysis: Enozerinib demonstrated favorable tolerability with mostly Grade 1 or 2 adverse events, and only three patients discontinued treatment due to adverse reactions, suggesting a safety profile that outperforms competitor therapies.
- Performance in Brain Metastases: Among patients receiving the 80 mg dose, enozertinib achieved a 100% intracranial ORR and a 93% disease control rate (DCR), showcasing its exceptional efficacy in patients with brain metastases and reinforcing its competitive edge in the market.
- Future Development Plans: ORIC plans to update data in mid-2026 and may initiate a Phase 3 trial, reflecting the company's confidence in enozertinib and its strategic positioning in the oncology sector.
See More
ORIC Pharmaceuticals Reports 67% ORR in 1L Patients for Enozerinib at ESMO Asia 2025
- Clinical Trial Results: At the ESMO Asia Congress 2025, ORIC Pharmaceuticals announced that the Phase 1b trial of enozertinib achieved a 67% objective response rate (ORR) in first-line patients with EGFR exon 20 mutations, indicating strong efficacy that may surpass competitor benchmarks in treating NSCLC.
- Safety Analysis: Enozerinib demonstrated good tolerability with mostly Grade 1 or 2 treatment-related adverse events (TRAEs) and no significant off-target toxicities, as only three patients discontinued treatment due to TRAEs, highlighting its safety profile in clinical applications.
- Performance in Brain Metastasis Patients: Among patients receiving the 80 mg dose, enozertinib achieved a 100% intracranial ORR and a 93% disease control rate (DCR), underscoring its effectiveness in patients with brain metastases and reinforcing its potential in treating complex cases.
- Future Development Plans: ORIC plans to update data in mid-2026 and advance enozertinib into Phase 3 trials, indicating the company's confidence in the drug and its potential competitiveness in the market.
See More
